About

Built by a retail trader.
For retail traders.

BiotechSign exists because PDUFA calendars, Form 4 filings, and clinical trial data were all public — and scattered across a dozen sources nobody had bothered to connect.

The Origin

Richard Garrett built these tools because he needed them. Not as a startup. Not with a pitch deck. Not after a Series A. He built them the way a retail trader with 40 years of IT experience and a functioning bullshit detector actually solves problems — by noticing that the data he needed existed, was public, and nobody had bothered to make it useful for people who don't have a Bloomberg terminal and a six-figure research budget.

That's the whole origin story. No pivot. No vision statement.

Who Built This

Richard is a Gen X IT consultant who has spent four decades in the trenches — back when "the cloud" was just a weather report and you actually had to know what you were doing to ship software. He's worked across the full stack of enterprise IT long enough to remember when "agile" wasn't a buzzword, it was just Tuesday. He has also, not metaphorically, dived with sharks for NASA. That one's real. Read it again if you need to.

His operating doctrine — what he calls Guerilla Rinzai — is what happens when you combine the no-resources discipline of guerilla warfare with the zero-ceremony directness of Rinzai Zen. No drift. No fluff. No six-week planning cycles for a three-hour fix. You see the problem, you solve the problem, you move.

The tools at Guerilla Finance Inc. exist because of that doctrine: built fast, built lean, and built to give retail traders the same data edge that institutional shops pay six figures a year for.

What We Track

SEC EDGAR
Form 4 insider filings, 8-K catalysts, S-3 shelf registrations
FDA.gov
PDUFA dates, advisory committee meetings, approval letters
ClinicalTrials.gov
Active trial counts by phase for 950+ biotech companies
DilutionWatch
Dilution scores, float data, short interest, warrant overhang
StonkWhisper
Convergence scoring, whale activity, dark pool, wire feed
FINRA
Short interest data, off-exchange (dark pool) volume, ATS transparency
Yahoo Finance
Latest news headlines via RSS

Methodology: How BiotechSign Scores Companies

Every biotech company in our coverage universe receives a BTS Catalyst Score (0-100) and a corresponding Catalyst Grade (A through F). These are computed daily from multiple independent signal categories:

FDA Pipeline Analysis
PDUFA target action dates, advisory committee (AdCom) meetings, and NDA/BLA submission status from FDA.gov.
Clinical Trial Data
Active trial counts by phase (I-IV), trial status changes, and therapeutic indication breadth from ClinicalTrials.gov.
Insider Trading Intelligence
SEC Form 4 insider purchases and sales, cluster buying patterns, and transaction dollar volumes from SEC EDGAR.
Dilution Risk Scoring
S-3 shelf registrations, ATM offerings, PIPE deals, warrant overhang, and cash runway estimates via DilutionWatch.
Dark Pool & Sentiment
Off-exchange (dark pool) volume from FINRA ATS data, short interest, and social/wire sentiment via StonkWhisper.
Convergence Signal
A proprietary indicator that fires when multiple independent signal types align simultaneously for a single ticker, suggesting elevated catalyst density.

The weighted combination of these signals produces the Catalyst Score. Grades map as: A (80-100), B (60-79), C (40-59), D (20-39), F (0-19). Scores are recalculated daily as new filings, trial updates, and FDA actions are ingested.

The Fleet

BiotechSign is part of the Guerilla Finance Inc. platform fleet. Each tool came from the same place: Richard sitting at a screen, watching something happen, and thinking: there should be a tool for this. Then building it. Usually before lunch.

The Mission

Guerilla Finance Inc. is the vehicle. The mission is simple: democratize the data for the people, delivered at a price point that doesn't require you to work at a hedge fund to afford it.

RG
Richard Garrett — Founder, Guerilla Finance Inc.
40 years IT. Retail trader. NASA shark diver. Builder of tools that institutional desks charge six figures for and retail traders actually need.
Not financial or investment advice. The content, data, tools, and analysis provided by Guerilla Finance Inc. and its properties — including BiotechSign, DilutionWatch, StonkWhisper, and H1BWageCheck — are for informational and educational purposes only. Nothing on these platforms constitutes financial, investment, legal, tax, or professional advice of any kind. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes (approval or rejection decisions) that can result in total loss of investment. A single PDUFA decision can move a stock 50% or more in either direction. Past performance is not indicative of future results. All data is sourced from publicly available records and is provided as-is without warranty of accuracy, completeness, or timeliness. You assume all risk associated with any investment or financial decision you make. Always conduct your own due diligence and consult a licensed financial advisor, attorney, or other qualified professional before making any investment decisions. Guerilla Finance Inc. is not a registered investment advisor, broker-dealer, or financial institution.